Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001223251 | SCV001395390 | uncertain significance | Nephronophthisis | 2021-08-26 | criteria provided, single submitter | clinical testing | This sequence change replaces proline with serine at codon 1303 of the NPHP3 protein (p.Pro1303Ser). The proline residue is moderately conserved and there is a moderate physicochemical difference between proline and serine. This variant is present in population databases (rs373728120, ExAC 0.004%). This variant has not been reported in the literature in individuals affected with NPHP3-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV002480735 | SCV002793544 | uncertain significance | Renal-hepatic-pancreatic dysplasia 1; Nephronophthisis 3; NPHP3-related Meckel-like syndrome | 2021-11-04 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004740620 | SCV005364451 | uncertain significance | NPHP3-related disorder | 2024-05-24 | no assertion criteria provided | clinical testing | The NPHP3 c.3907C>T variant is predicted to result in the amino acid substitution p.Pro1303Ser. This variant has not been reported in the literature in individuals with NPHP3-related disorders. This variant is reported in 0.0039% of alleles in individuals of European (non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |